RSS Feeds
Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia
- Issa Khouri, MD; and
- Richard Champlin, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Michallet and colleagues [1] correctly assert that it is unknown how the results collected from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation regarding allogeneic bone marrow transplantation for CLL compare with those of conventional therapies. To answer this question, we studied allogeneic bone marrow and stem-cell transplantation for patients with advanced CLL [2, 3] who failed to respond to fludarabine, an agent considered by many to be the most effective conventional treatment for CLL. These patients usually have a poor prognosis [4]. Sixteen patients had transplantation; 13 were refractory, and 3 had untested relapse after receiving fludarabine. Twelve had Rai stage 4 disease. The incidence of complete remission was 87%. No patients died of acute graft-versus-host disease. Currently, 56% of patients continue to be in remission, as documented by flow cytometry and molecular studies; survivors have been followed for a median of 36 months (range, 3 to 60 months). These data are encouraging, and we believe that allogeneic transplantation is indicated and can be beneficial in this setting.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
